Latest Property Portfolio News

Rural Funds Group has lodged replacement constitutions for its key trusts, Rural Funds Trust and RF Active, refining governance, stapling mechanics, and compliance frameworks to align with evolving regulatory standards.

Goodman NZ surged to a $248 million statutory profit in FY26, propelled by strong property revaluations and leasing gains, while advancing major development projects and transitioning to a stapled group structure.

Ryman Healthcare reported a substantial reduction in net loss for FY26 alongside its first positive free cash flow in over a decade, driven by operational improvements, refinancing, and land divestments.

New Zealand Rural Land Company posted a stable FY25 with $7.9 million net profit and raised FY26 AFFO guidance, shifting to quarterly dividends targeting 90-100% of AFFO amid a board refresh.

Archer Materials progresses its Biosensor platform from alpha to beta prototype, targeting manufacturability and external validation with expanded diagnostic applications including lithium monitoring.

Fluence Corporation Limited (ASX: FLC) reports a 52% revenue surge in FY2025 driven by strategic growth in Smart Product Solutions and recurring revenue, alongside progress on a major Ivory Coast water treatment plant.

Entropy Neurodynamics has bolstered its intellectual property portfolio with a new US provisional patent application for TRP-8803, following compelling Phase 2a data showing a 75% response rate in treatment-resistant IBS patients.

Stockland reports strong leasing growth and development momentum in 3Q26, highlighting new data centre and land lease partnerships while maintaining FY26 guidance.

Actinogen Medical’s pivotal XanaMIA trial clears a key interim hurdle with the Data Monitoring Committee endorsing continuation, while a $16.8 million capital raise and non-dilutive funding bolster its balance sheet ahead of final results due November 2026.

Zeotech pushed forward its AusPozz™ metakaolin commercialisation with extended and new MOUs, progressed key Toondoon project approvals amid rising contractor costs, and launched live methane control trials.

Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.

Entropy Neurodynamics has reported encouraging early clinical outcomes from its pioneering intravenous psilocin therapy for Binge Eating Disorder, alongside a patent grant that strengthens its intellectual property moat.